Wednesday, November 28, 2018
Novacyt, an international specialist in clinical diagnostics, today announces its molecular testing division, Primerdesign Ltd. (Primerdesign), has signed an exclusive supply agreement worth a minimum of $3 million with Genesis Diagnostics, a US-based full service diagnostic laboratory that offers clinical diagnostic testing, oral fluid drug testing and services focused on drug monitoring, substance abuse programmes, infectious disease, and personalised medicine.
Primerdesign will develop and supply 384 well plate molecular assay panels for respiratory, women’s health, sexually transmitted, wound and urinary tract infections for Genesis Diagnostics to use in its clinical service laboratory based in Langhorne, Pennsylvania.
Under the terms of the agreement, Primerdesign will be appointed the exclusive product manufacturer of the panel for a minimum of five years. The supply of product is expected to commence in early 2019 and Genesis Diagnostics will purchase minimum quantities of product to the value of $600,000 per year.
Alan Miller, Executive Chairman of Genesis Diagnostics, commented:
“We have been looking for some time to find a suitable molecular manufacturer to help us with our growing demand for specialist molecular diagnostics. As an expert in molecular diagnostic assay design and development, Primerdesign is therefore the ideal partner of choice for Genesis Diagnostics. We have been impressed with Primerdesign’s assay development expertise and manufacturing ability to deliver a high-quality service and I am pleased to enter this strategic agreement to expand our offering in the US market.”
Graham Mullis, Group CEO of Novacyt, added:
“I am delighted that we are entering into a supply agreement with Genesis Diagnostics. The agreement builds on our broad product offering and the increasing geographic reach of our molecular diagnostics business. It also highlights Primerdesign’s pivotal role in assay development as we continue to grow our relationships with leading diagnostic companies, further increasing our reputation as a leading clinical assay development and supplies partner. The minimum revenues expected from this partnership further support our investment in our B2B partnerships strategy and we expect Genesis Diagnostics to order significantly more than the contracted minima disclosed above.”
